Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia	B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 2	2026-10-06		NCT07061951

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope at Irvine Lennar	Irvine	United States	104
City of Hope Comprehensive Cancer Center	Duarte	United States	263
Dana-Farber Cancer Institute	Boston	United States	626
Huntsman Cancer Institute/University of Utah	Salt Lake City	United States	249
NYP/Weill Cornell Medical Center	New York	United States	128
Ohio State University Comprehensive Cancer Center	Columbus	United States	548
UNC Lineberger Comprehensive Cancer Center	Chapel Hill	United States	243
University of California Davis Comprehensive Cancer Center	Sacramento	United States	299
UPMC Hillman Cancer Center	Pittsburgh	United States	330